GlaxoSmithKline to reveal more drug secrets

LONDON (Reuters) – GlaxoSmithKline, criticized in the past for keeping important information about its medicines to itself, is to lift the lid on more of its drug secrets. Three months after GSK was fined $3 billion for fraud in the United States, where prosecutors accused it of concealing safety issues, chief executive Andrew Witty said on Thursday detailed data from its clinical trials would be made available to other researchers. That would include anonymised patient-level results that sit behind clinical trials of approved and failed drugs. …